GRFS - Convalescent Plasma Found to Reduce COVID-19 Death Rate in New Study
A clinical research study led by the Mayo Clinic has achieved promising results in COVID-19 patients by administering them so-called "convalescent plasma" -- plasma enriched with high levels of antibodies from people who have recovered from the novel coronavirus.
According to a Wall Street Journal article about the study, which was conducted with roughly 3,000 patients, those who were administered such plasma three days or less after diagnosis showed what the Journal described as a "mortality rate" of 6.6% after seven days following the infusion. (That figure, in fact, appears to be the case fatality rate). By comparison, patients receiving plasma containing low levels of antibodies four days after diagnosis had a rate of 13.3%.
Image source: Getty Images.